PULMONOLOGY & SLEEP MEDICINE
Professional organization affiliations
RESEARCH HIGHLIGHTS
RANKED 10 th IN THE NATION *
Funded by the NIH ■ Clinical trial to evaluate pharmacokinetics and safety of slow release dehydroepiandrosterone (Phase IIa) ■ Obesity and childhood asthma: The role of adipose tissue ■ Scientific innovation for personalized severe asthma management Funded by the Cystic Fibrosis Foundation ■ Streamline treatment of pulmonary exacerbation in pediatrics (STOP PEDS RCT)
Pulmonologists at Riley Children’s hold leadership positions in the following organizations: ■ American Academy of Sleep Medicine ■ Cystic Fibrosis Foundation ■ Society of Behavioral Sleep Medicine ■ American Thoracic Society
Pulmonology and sleep medicine specialists at Riley Children’s Health provide advanced, child-focused and family-centered clinical care to children with respiratory and sleep disorders. Our team serves as a
specialized medical home that works together with hospital and community-based providers to treat children with chronic respiratory illnesses. Riley Pulmonology & Sleep Medicine provides services in seven locations across Indiana.
Premier programs
131 research publications in 2025
TOP DISTINCTIONS
Pulmonology and Sleep Study Volume: 2023 – 2025 Pulmonary function test 10,785 2023 11,403 2024
Cystic Fibrosis Program A national leader in
Bronchopulmonary Dysplasia (BPD) Program
■ Only pediatric pulmonary program in the U.S. with a National Institutes of Health (NIH) program project grant (P01) to develop asthma treatments Primary ciliary dyskinesia (PCD) ■ One of the few centers nationally offering airway epithelial culture for ciliary function analysis, high-speed video microscopy with bead tracking, and PCD immunofluorescence; receives samples for analysis from across the country, including from the NIH’s PCD program ■ One of three programs in the U.S. to be selected as a founding member of the PCD Foundation’s Therapeutics Development Network Riley Sleep Disorders Center ■ Home of a multidisciplinary hypoglossal nerve stimulation program; features implantable neural transmutation therapy (Inspire®) ■ Only program in Indiana delivering Inspire therapy to adolescents with Down syndrome and obstructive sleep apnea who are unable to tolerate CPAP therapy
NOTABLE PUBLICATIONS
A founding member of the BPD Collaborative, Riley Children’s delivers integrated inpatient/ outpatient BPD care to optimize transition to home and long-term outcomes with significant reduction in tracheostomies and post-NICU complications. > Learn more. Pulmonary Hypertension Program Fully integrated partnership between Riley pulmonology and cardiology provides expert, coordinated care for children with pulmonary hypertension as a primary diagnosis or resulting from another medical condition. Novel therapies and procedures ■ High-speed video microscopy (HSVM) ■ Immunofluorescence microsopy (IFM) ■ Mucociliary clearance analysis (MCC) ■ Noninvasive thio-bound nitric oxide device ■ Nasal epithelial cell theratyping ■ Testing for response to CFTR modulators Advancing its interventional bron- choscopy program, in 2026 Riley Pulmonology introduced cryobron- choscopy, expanding access to leading-edge procedures for patients with complex pulmonary conditions.
transitioning pediatric cystic fibrosis patients to adult care, Riley Children’s received a Cystic Fibrosis Foundation Quality Improvement Award for seeking to minimize patient risk during this critical transition. Our nationally recognized program also offers Trikafta® to mothers pregnant with a child with CF. High-Risk Asthma Program A founding member of the Severe Pediatric Asthma Consortium, Riley Children’s has one of the largest, highest- volume severe pediatric asthma centers in the nation. ■ 392 unique patients served in 2025 (program’s all-time high) with 111 new patients ■ Number of patients treated with biologic therapy increased from 41 in 2020 to 97 in 2025 ■ Program includes a dedicated psychologist and pediatrician
11,862 2025
CHEST Pulmonary: September 2025 Metabolic medications and youth hospitalizations for asthma: A pre-post quasi-experimental study The Journal of Allergy and Clinical Immunology: April 2025 Mitochondrial DNA copy number variation in asthma risk, severity and exacerbations The Lancet Respiratory Medicine: January 2025 Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: Results from two major longitudinal asthma cohorts American Journal of Respiratory and Critical Care Medicine: September 2025 Treatment of nicotine use in adolescents under 18 years of age: An official American Thoracic Society clinical practice guideline Pediatric Pulmonology: April 2025 Pediatric pulmonology 2024 year in review: Rare and diffuse lung disease Journal of Cystic Fibrosis: March 2025 Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor
Bronchoscopy
802 2023
875 2024
838 2025
Sleep study 3,270 2023
3,530 2024
3,566 2025
Program accreditations ■ Cystic Fibrosis Foundation
DIVISION CHIEF James F. Chmiel, MD, MPH Professor of Pediatrics, IU School of Medicine > Connect with Dr. Chmiel on Doximity.
■ American Academy of Sleep Medicine ■ Primary Ciliary Dyskinesia Foundation ■ Therapeutics Development Network ■ Pulmonary Hypertension Association
24 board certified physicians
See full team member list >
Combining sleep medicine and psychology, the Hypersomnia Program, launched in 2023, treats patients with excessive daytime sleepiness and central hypersomnia.
* Tied for 10th
Refer a patient online
T 317.948.7208
Made with FlippingBook flipbook maker